Related Experiment Video
Updated: Jul 3, 2026
A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats
Published on: November 6, 2019
Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma
Genell D Hilton1, Bogdan A Stoica, Kimberly R Byrnes
1Department of Neuroscience, Georgetown University Medical Center, Washington, District of Columbia 20057, USA.
Abstract:
Traumatic brain injury (TBI) causes both direct and delayed tissue damage. The latter is associated with secondary biochemical changes such as cell cycle activation, which leads to neuronal death, inflammation, and glial scarring. Flavopiridol--a cyclin-dependent kinase (CDK) inhibitor that is neither specific nor selective--is neuroprotective. To examine the role of more specific CDK inhibitors as potential neuroprotective agents, we studied the effects of roscovitine in TBI. Central administration of roscovitine 30 mins after injury resulted in significantly decreased lesion volume, as well as improved motor and cognitive recovery. Roscovitine attenuated neuronal death and inhibited activation of cell cycle pathways in neurons after TBI, as indicated by attenuated cyclin G1 accumulation and phosphorylation of retinoblastoma protein. Treatment also decreased microglial activation after TBI, as reflected by reductions in ED1, galectin-3, p22(PHOX), and Iba-1 levels, and attenuated astrogliosis, as shown by decreased accumulation of glial fibrillary acidic protein. In primary cortical microglia and neuronal cultures, roscovitine and other selective CDK inhibitors attenuated neuronal cell death, as well as decreasing microglial activation and microglial-dependent neurotoxicity. These data support a multifactorial neuroprotective effect of cell cycle inhibition after TBI--likely related to inhibition of neuronal apoptosis, microglial-induced inflammation, and gliosis--and suggest that multiple CDKs are potentially involved in this process.
Insights
Roscovitine, a specific cyclin-dependent kinase (CDK) inhibitor, reduced brain damage and improved recovery after traumatic brain injury (TBI). It protected neurons, decreased inflammation, and inhibited glial scarring, suggesting CDK inhibition as a therapeutic strategy.
Area of Science:
- Neuroscience
- Pharmacology
- Cell Biology
Background:
- Traumatic brain injury (TBI) induces secondary damage via cell cycle activation, leading to neuronal death, inflammation, and glial scarring.
- Non-selective cyclin-dependent kinase (CDK) inhibitors like flavopiridol show neuroprotection, prompting investigation into specific CDK inhibitors.
Purpose of the Study:
- To investigate the neuroprotective potential of roscovitine, a specific CDK inhibitor, in the context of TBI.
- To elucidate the mechanisms underlying roscovitine's effects on neuronal survival, inflammation, and glial responses post-TBI.
Main Methods:
- Central administration of roscovitine in a TBI model.
- Assessment of lesion volume, motor and cognitive function.
- Evaluation of neuronal death, cell cycle markers (cyclin G1, retinoblastoma protein phosphorylation), microglial activation (ED1, galectin-3, p22(PHOX), Iba-1), and astrogliosis (glial fibrillary acidic protein).
- In vitro studies using primary cortical microglia and neuronal cultures.
Main Results:
- Roscovitine treatment significantly reduced lesion volume and improved motor and cognitive recovery after TBI.
- Roscovitine attenuated neuronal death and inhibited cell cycle pathway activation in neurons.
- Treatment decreased microglial activation and astrogliosis.
- In vitro, roscovitine and other selective CDK inhibitors reduced neuronal death and microglial activation.
Conclusions:
- Roscovitine exhibits multifactorial neuroprotective effects after TBI, including inhibition of neuronal apoptosis, inflammation, and gliosis.
- Selective CDK inhibition represents a promising therapeutic strategy for TBI.
- Multiple CDKs are implicated in the secondary injury cascade following TBI.
Related Concept Videos
01:28Traumatic Brain Injury l: Introduction
01:22Alzheimer's Disease: Treatment